Selection of non-small-cell lung cancer patients for...

Chemistry: analytical and immunological testing – Nuclear magnetic resonance – electron spin resonance or other...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C436S086000, C436S171000, C435S006120, C435S069900, C435S372000, C702S020000, C702S179000

Reexamination Certificate

active

07858389

ABSTRACT:
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer (NSCLC) patient is likely to benefit from a monoclonal antibody drug targeting an epidermal growth factor receptor pathway. A mass spectrum is obtained from a sample (e.g. blood sample) from the patient. One or more predefined pre-processing steps are performed on the mass spectrum. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained after the pre-processing steps have been performed. Such values are used in a classification algorithm using a training set comprising class-labeled spectra produced from samples from other patients to identify the patient as being likely to benefit from treatment with the drug.

REFERENCES:
patent: 7736905 (2010-06-01), Roder et al.
patent: 2005/0048547 (2005-03-01), Zhao et al.
patent: 2005/0164218 (2005-07-01), Agus et al.
patent: 2005/0267689 (2005-12-01), Tsypin
patent: 2006/0029574 (2006-02-01), Albitar et al.
patent: 2007/0231921 (2007-10-01), Röder et al.
patent: WO 2004/012588 (2004-02-01), None
patent: WO 2005/010492 (2005-02-01), None
patent: WO 2005/098445 (2005-10-01), None
Written Opinion of the International Searching Authority in PCT/US2007/007467 dated Nov. 8, 2007.
International Search Report in PCT Application Publication No. WO 2007/126758, published Nov. 8, 2007.
Fleming et al. “Windowed mass selection method: a new data processing algorithm for liquid chromatography-mass spectrometry data”, Journal of Chromatography A, vol. 849, pp. 71-85 (1999).
Senko et al., “Determination of monoisotopic masses and ion population for large biomolecules from resolved isotopic distribution”, Journal of the American Society for Mass Spectrometry, vol. 6, pp. 229-233 (1995).
Gras et al., “Improving protein identification from peptide mass fingerprinting through a parameterized multi-level scoring algorithm and an optimized peak detection”, Electrophoresis, vol. 20, pp. 3535-3550 (1999).
Metro, et al., “Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)”, Reviews on Recent Clinical Trials, vol. 1, No: 1, pp. 1-13 (2006).
Taguchi, et al., “Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study”, Journal of the National Cancer Institute, vol. 99, Issue 11, pp. 838-846 (2007).
Ladanyi, et al., “Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond”, Modern Pathology, vol. 21, pp. S16-S22 (2008).
Office Action dated Feb. 6, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
Amendment and pending claims filed Apr. 7, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
U.S. Appl. No. 12/321,393 filed Jan. 20, 2009.
U.S. Appl. No. 12/321,394 filed Jan. 20, 2009.
Extended European Search Report in EP 07754043.3, dated Jun. 8, 2009.
U.S. Office Action dated Aug. 25, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
Lynch et al.,Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib, The New England Journal of Medicine, vol. 350, No. 21, pp. 2129-2139 (2004).
Alfassi,On the Normalization of a Mass Spectrum for Comparison of Two Spectra, American Society for Mass Spectrometry, vol. 15, pp. 385-387 (2004).
Bhanot et al.,A Robust Meta-Classification Strategy for Cancer Detection from MS Data, Proteomics, vol. 6, pp. 592-604 (2006).
Koenker et al.,Quantile Smoothing Splines, Biometrika vol. 81, pp. 673-680 (1994).
Eilers,Parametric Time Warping, Analytical Chemistry, vol. 76, No. 2, pp. 401-411 (2004).
Extended European Search Report dated Aug. 25, 2010 in European Application No. 10003343.0.
Bhanot et al.A robust meta-classification strategy for cancer detection from MS dataProteomics, vol. 6, NR 2, pp. 592-607 (Jan. 2006).
Reyzer et al.MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery, Journal of Proteome Research vol. 4, No. 4, pp. 1138-1142 (2005).
Yanagisawa et al.Proteomic patterns of tumour subsets in non-small-cell lung cancer, The Lancet, vol. 362, pp. 433-439 (Aug. 9, 2003).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Selection of non-small-cell lung cancer patients for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selection of non-small-cell lung cancer patients for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selection of non-small-cell lung cancer patients for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4152614

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.